3050.0: Monday, November 13, 2000 - 1:00 PM

Abstract #8196

Trends in the Use of New Antipsychotic Agents

Carolyn S Dewa, MPH, PhD1, Gary Remington, MD, PhD, FRCP(C)1, Paula Goering, RN, PhD1, and Joan Fearnley, MSc2. (1) Health Systems Research and Consulting Unit, Centre for Addiction and Mental Health, Clarke Division, 250 College Street, Toronto, ON M5T 1R8, Canada, (416) 535-8501 x4101, carolyn_dewa@camh.net, (2) Brogan, Inc

Research Objective: This analysis examines patterns of antipsychotic use after atypicals were introduced. It identifies affected sub-populations and posits how trends reflect clinical practice. Study Design: Data are from the Ontario Drug Benefit (ODB) program for 1992 to 1998. Like Medicaid, this provincially funded program serves two major populations: the elderly and the financially disadvantaged. The analysis begins by examining overall trends in antipsychotic use as compared with all psychotherapeutic agents. It goes on to identify a sub-population of ODB participants who were “continuous users” and follows their antipsychotic use over two years. Principle Findings: Total antipsychotic expenditures rose by 300%, while the number of claimants grew by 25% and cost/claimant increased by 250%. “Continuous users” primarily fell into two age groups: (i) 25-44, and (ii) over 80. Conclusions: The rapid increase in atypical use, combined with their much higher costs led to a dramatic rise in antipsychotic costs. Whether their use is associated with cost offsets is a subject of debate, although there is evidence to support this. The bimodal distribution of “continuous users” may be explained along diagnostic lines, although it is likely that use of atypicals will continue to rise across all ages.

Learning Objectives: At the end of the session the participant will be able to: 1. Describe trends in antipsychotic use. 2. Discuss clinical implications of these trends

Keywords: Mental Health Care,

Presenting author's disclosure statement:
Organization/institution whose products or services will be discussed: None
I do not have any significant financial interest/arrangement or affiliation with any organization/institution whose products or services are being discussed in this session.

The 128th Annual Meeting of APHA